Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathologic Misclassification of Renal Cell Carcinoma in Adolescents and Young Adults.

Cancers·2026

Same author

Protocol for In Vivo Two-Photon FCS to Measure Nanocarrier Number and Flow Velocity in Mouse Cerebral Microvasculature.

Bio-protocol·2026

Same author

Precision oncology's translation gap-Can molecular tumor boards bridge it?

PLoS medicine·2026

Same author

Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.

Therapeutic advances in medical oncology·2026

Same author

mTORC1-Dependent Regulation of the CCL24-CCR3 Axis Controls Granuloma Formation and Maintenance in Sarcoidosis.

Molecular and cellular biology·2026

Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Author Spotlight: Exploring Macrophage Immunometabolism Through Lentiviral Vector-Mediated Gene Manipulation

Author Spotlight: Exploring Macrophage Immunometabolism Through Lentiviral Vector-Mediated Gene Manipulation

Published on: February 16, 2024

M1 Macrophage-Engineered Vesicles Have Anti-Cancer Activity in Ovarian Cancer.

Connie D Cao^1,2, J Robert McCorkle¹, Derek B Allison³

¹Markey Cancer Center, University of Kentucky, Lexington, KY.

Cancer Nanotechnology

|January 12, 2026

Summary

Engineered extracellular vesicles (EVs) derived from M1 macrophages show promise for ovarian cancer treatment. These macrophage-derived EVs (MEVs) demonstrated efficacy comparable to cisplatin in preclinical models, warranting further investigation.

Keywords:

engineered vesicles extracellular vesicles immunotherapy ovarian cancer

More Related Videos

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

Author Spotlight: Exploring Macrophage Immunometabolism Through Lentiviral Vector-Mediated Gene Manipulation

Author Spotlight: Exploring Macrophage Immunometabolism Through Lentiviral Vector-Mediated Gene Manipulation

Published on: February 16, 2024

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Area of Science:

Oncology
Nanotechnology
Immunology

Background:

Ovarian cancer is a leading cause of cancer-related death in women, often diagnosed at advanced stages.
Extracellular vesicles (EVs) are nanoparticles involved in cell-to-cell communication, explored for drug delivery and tumor microenvironment modulation.
Artificial cell-derived vesicles (ACDVs) from M1 macrophages can repolarize M2 macrophages to M1 and target tumor cells in vitro.

Purpose of the Study:

To generate engineered EVs (EEVs) from M1 macrophages loaded with cisplatin (C-MEVs) or empty (E-MEVs).
To evaluate the therapeutic potential of E-MEVs and C-MEVs in an ovarian cancer mouse xenograft model.

Main Methods:

Engineered EVs (EEVs) were created by disrupting M1 macrophage membranes.
Cisplatin was loaded into some EEVs to create C-MEVs; others remained empty (E-MEVs).
E-MEVs and C-MEVs were tested in an ovarian cancer mouse xenograft model.

Main Results:

Both E-MEVs and C-MEVs significantly reduced weight loss in the mouse model.
The therapeutic activity of E-MEVs and C-MEVs was equivalent to cisplatin.
These engineered EVs showed improved activity compared to control groups.

Conclusions:

Macrophage-derived EVs (MEVs) show therapeutic potential for ovarian cancer.
Further development of MEVs is warranted for ovarian cancer treatment.
Engineered EVs offer a promising strategy for ovarian cancer therapy.